Redmile Group, LLC Amicus Therapeutics, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q2 2024

A detailed history of Redmile Group, LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 10,595,089 shares of FOLD stock, worth $124 Million. This represents 6.85% of its overall portfolio holdings.

Number of Shares

10,595,089

Previous 13,257,286 20.08%

Holding current value

$124 Million

Previous $156 Million 32.7%

% of portfolio

6.85%

Previous 6.16%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$9.04 - $11.75 $24.1 Million - $31.3 Million	-2,662,197 Reduced 20.08%	10,595,089 $105 Million
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $18 Million - $22.4 Million	-1,571,035 Reduced 10.59%	13,257,286 $156 Million
Q4 2023 Feb 14, 2024	SELL	$9.97 - $14.52 $47.2 Million - $68.8 Million	-4,738,640 Reduced 24.22%	14,828,321 $210 Million
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $13.1 Million - $16.2 Million	1,220,100 Added 6.65%	19,566,961 $246 Million
Q1 2023 May 15, 2023	SELL	$10.91 - $13.54 $20.8 Million - $25.8 Million	-1,902,928 Reduced 9.4%	18,346,861 $203 Million
Q4 2022 Feb 14, 2023	SELL	$9.89 - $12.7 $14.5 Million - $18.7 Million	-1,469,402 Reduced 6.77%	20,249,789 $247 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $4.32 Million - $5.61 Million	-439,700 Reduced 1.98%	21,719,191 $227 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $1.06 Million - $1.9 Million	-170,495 Reduced 0.76%	22,158,891 $238 Million
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $3.05 Million - $4.83 Million	-386,700 Reduced 1.7%	22,329,386 $211 Million
Q4 2021 Feb 14, 2022	BUY	$9.82 - $12.44 $18.8 Million - $23.8 Million	1,916,783 Added 9.22%	22,716,086 $262 Million
Q2 2021 Aug 16, 2021	SELL	$8.71 - $10.72 $2.74 Million - $3.37 Million	-314,811 Reduced 1.49%	20,799,303 $201 Million
Q1 2021 May 17, 2021	BUY	$9.2 - $23.86 $4.54 Million - $11.8 Million	493,624 Added 2.39%	21,114,114 $209 Million
Q4 2020 Feb 16, 2021	SELL	$13.47 - $24.89 $33.1 Million - $61.1 Million	-2,455,317 Reduced 10.64%	20,620,490 $476 Million
Q3 2020 Nov 16, 2020	SELL	$12.89 - $15.89 $24.1 Million - $29.7 Million	-1,868,888 Reduced 7.49%	23,075,807 $326 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $2.1 Million - $3.72 Million	-236,805 Reduced 0.94%	24,944,695 $376 Million
Q1 2020 May 15, 2020	SELL	$6.63 - $11.16 $188,716 - $317,658	-28,464 Reduced 0.11%	25,181,500 $233 Million
Q4 2019 Feb 14, 2020	BUY	$7.48 - $10.75 $18.1 Million - $26 Million	2,419,830 Added 10.62%	25,209,964 $246 Million
Q3 2019 Nov 14, 2019	SELL	$8.02 - $13.25 $20,050 - $33,125	-2,500 Reduced 0.01%	22,790,134 $183 Million
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $34.8 Million - $45.7 Million	3,176,572 Added 16.19%	22,792,634 $284 Million
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $113 Million - $157 Million	11,292,845 Added 135.68%	19,616,062 $267 Million
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $665,372 - $1.07 Million	-79,400 Reduced 0.94%	8,323,217 $79.7 Million
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $24.5 Million - $34.9 Million	-2,109,115 Reduced 20.06%	8,402,617 $102 Million
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $2.98 Million - $3.88 Million	-226,926 Reduced 2.11%	10,511,732 $164 Million
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $9.81 Million - $12.2 Million	712,888 Added 7.11%	10,738,658 $0
Q4 2017 Feb 14, 2018	SELL	$12.51 - $16.24 $12.3 Million - $16 Million	-986,791 Reduced 8.96%	10,025,770 $144 Million
Q3 2017 Nov 14, 2017	BUY	$11.74 - $15.78 $129 Million - $174 Million	11,012,561	11,012,561 $166 Million

Others Institutions Holding FOLD

# of Institutions

279

Shares Held

324M

Call Options Held

260K

Put Options Held

261K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $3.27B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Amicus Therapeutics, Inc. Transaction History